Login to Your Account



InterMune Licenses Rights To Phase II Candidate For Fibrosis

By Karen Young


Tuesday, April 9, 2002
InterMune Inc. licensed worldwide rights to develop and commercialize pirfenidone for all fibrotic diseases, including renal, liver and pulmonary fibrosis a drug candidate that plays right into the company’s field of expertise. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription